Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2017, Article ID 1212609, 8 pages
https://doi.org/10.1155/2017/1212609
Research Article

Synthesis and In Vitro AMPK Activation of Cycloalkyl/Alkarylbiguanides with Robust In Vivo Antihyperglycemic Action

1Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, 62209 Cuernavaca, MOR, Mexico
2Departamento de Farmacobiología, Cinvestav-Coapa, 14330 Ciudad de México, Mexico
3Laboratorio de Nutrición Experimental, Instituto Nacional de Pediatría, 04150 Ciudad de México, Mexico

Correspondence should be addressed to Samuel Estrada-Soto; xm.meau@hcone and Gabriel Navarrete-Vázquez; xm.meau@eterravan_leirbag

Received 16 August 2017; Accepted 22 October 2017; Published 15 November 2017

Academic Editor: Teodorico C. Ramalho

Copyright © 2017 Erika Gutierrez-Lara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 32, supplement 1, pp. S62–S67, 2009. View at Publisher · View at Google Scholar
  2. S. Meng, J. Cao, Q. He et al., “Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex,” The Journal of Biological Chemistry, vol. 290, no. 6, pp. 3393–3802, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Moreno-Arriola, M. El Hafidi, D. Ortega-Cuéllar, and K. Carvajal, “AMP-activated protein kinase regulates oxidative metabolism in Caenorhabditis elegans through the NHR-49 and MDT-15 transcriptional regulators,” PLoS ONE, vol. 11, no. 1, Article ID 0148089, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. K. O. Cameron and R. G. Kurumbail, “Recent progress in the identification of adenosine monophosphate-activated protein kinase (AMPK) activators,” Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 21, pp. 5139–5148, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Yang, H. Sha, R. L. Davisson, and L. Qi, “Phenformin activates the unfolded protein response in an AMP-activated protein kinase (AMPK)-dependent manner,” The Journal of Biological Chemistry, vol. 288, no. 19, pp. 13631–13638, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Hidalgo-Figueroa, J. J. Ramírez-Espinosa, S. Estrada-Soto et al., “Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual ppar α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches,” Chemical Biology & Drug Design, vol. 81, no. 4, pp. 474–483, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Hidalgo-Figueroa, G. Navarrete-Vázquez, S. Estrada-Soto et al., “Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation,” Biomedicine & Pharmacotherapy, vol. 90, pp. 53–61, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. M. N. Berry and D. S. Friend, “High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study.,” The Journal of Cell Biology, vol. 43, no. 3, pp. 506–520, 1969. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Albus, “Guide for the Care and Use of Laboratory Animals (8th edn)by the National Research Council of the NationalAcademiesWashington, DC: National Academies Press, 2011,” Laboratory Animals, vol. 46, no. 3, pp. 267-268, 2012. View at Publisher · View at Google Scholar
  10. J. A. García-Díaz, G. Navarrete-Vázquez, S. García-Jiménez et al., “Antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in streptozotocin-nicotinamide diabetic rats,” Biomedicine & Pharmacotherapy, vol. 83, pp. 667–675, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. E. J. Verspohl, “Recommended testing in diabetes research,” Planta Medica, vol. 68, no. 7, pp. 581–590, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. S. N. Goyal, N. M. Reddy, K. R. Patil et al., “Challenges and issues with streptozotocin-induced diabetes-a clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics,” Chemico-Biological Interactions, vol. 244, pp. 49–63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. R. R. Ortiz-Andrade, J. C. Sánchez-Salgado, G. Navarrete-Vázquez et al., “Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation,” Diabetes, Obesity & Metabolism, vol. 10, no. 11, pp. 1097–1104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. B. Silverman and M. W. Holladay, The organic chemistry of drug design and drug action, Academic Press, San Diego, Calif, USA, 3rd edition, 2014.
  15. H. R. Bridges, V. A. Sirviö, A.-N. A. Agip, and J. Hirst, “Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase,” BMC Biology, vol. 14, no. 1, article 65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Scudiero, E. Nigro, M. L. Monaco et al., “New synthetic AICAR derivatives with enhanced AMPK and ACC activation,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 31, no. 5, pp. 748–753, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Xu, Y. Chen, Y. Pan, G. L. Skiles, and M. Shou, “Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator,” Drug Metabolism and Disposition, vol. 37, no. 12, pp. 2330–2339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Taboureau and F. S. Jørgensen, “In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology,” Combinatorial Chemistry & High Throughput Screening, vol. 14, no. 5, pp. 375–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Navarrete-Vázquez, H. Torres-Gómez, S. Hidalgo-Figueroa et al., “Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 18, pp. 4575–4579, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Navarrete-Vázquez, A. Austrich-Olivares, B. Godínez-Chaparro et al., “Discovery of 2-(3,4-dichlorophenoxy)-N-(2-morpholin-4-ylethyl)acetamide: A selective σ1 receptor ligand with antinociceptive effect,” Biomedicine & Pharmacotherapy, vol. 79, pp. 284–293, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. E. J. Gutiérrez-Lara, G. Navarrete-Vázquez, A. Sánchez-López, and D. Centurión, “Pharmacological evaluation of metformin and N- benzylbiguanide, a novel analogue of metformin, on the vasopressor responses to adrenergic system stimulation in pithed rats with fructose-induced insulin resistance,” European Journal of Pharmacology, vol. 814, pp. 313–323, 2017. View at Publisher · View at Google Scholar